Hasan Korkaya

List of Publications by Year in Descending Order

58 papers	6,848 citations	32 h-index	65 g-index
65 ext. papers	7,597 ext. citations	8.8 avg, IF	5.62 L-index

#	Paper	IF	Citations
58	RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy. *Molecular Cancer Research*, **2021**, 19, 1486-1497	6.6	2
57	Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment. *Oncology Reports*, **2021**, 45, 1171-1181	3.5	11
56	Short-Term Diet Restriction but Not Alternate Day Fasting Prevents Cisplatin-Induced Nephrotoxicity in Mice. *Biomedicines*, **2020**, 8,	4.8	3
55	Deficiency Reduces Tumor Growth by Targeting Stem Cell Self-Renewal. *Cancer Research*, **2020**, 80, 3855-3866	10.1	5
54	Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors. *Signal Transduction and Targeted Therapy*, **2020**, 5, 264	21	2
53	Plasticity and Potency of Mammary Stem Cell Subsets During Mammary Gland Development. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6
52	Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model. *Nature Communications*, **2019**, 10, 1430	17.4	43
51	The co-chaperone UNC45A is essential for the expression of mitotic kinase NEK7 and tumorigenesis. *Journal of Biological Chemistry*, **2019**, 294, 5246-5260	5.4	13
50	The pleiotropic effects of TNF□n breast cancer subtypes is regulated by TNFAIP3/A20. *Oncogene*, **2019**, 38, 469-482	9.2	15
49	SRC Increases mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function. *Molecular and Cellular Biology*, **2018**, 38,	4.8	6
48	Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2 Breast Cancer. *Molecular Therapy - Nucleic Acids*, **2018**, 10, 317-330	10.7	49
47	Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer. *International Journal of Cancer*, **2018**, 143, 2177-2186	7.5	14
46	Thymoquinone protects DRG neurons from axotomy-induced cell death. *Neurological Research*, **2018**, 40, 930-937	2.7	5
45	expression in acute myeloid leukemia. *Oncotarget*, **2018**, 9, 7442-7452	3.3	4
44	The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. *Cancer Research*, **2018**, 78, 6728-6735	10.1	20
43	Thymoquinone prevents cisplatin neurotoxicity in primary DRG neurons. *NeuroToxicology*, **2018**, 69, 68-76	4.4	11
42	Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. *Cancer Immunology Research*, **2017**, 5, 330-344	12.5	20

41	Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. *Nature Communications*, **2017**, 8, 14979	17.4	185
40	HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model. *PLoS ONE*, **2017**, 12, e0178830	3.7	17
39	Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy. *Biomaterials*, **2016**, 104, 145-57	15.6	31
38	A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. *Cancer Research*, **2016**, 76, 480-90	10.1	27
37	Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. *Oncotarget*, **2016**, 7, 51408-51422	3.3	32
36	Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. *Oncotarget*, **2016**, 7, 69903-69915	3.9	40
35	Interplay between cell cycle and autophagy induced by boswellic acid analog. *Scientific Reports*, **2016**, 6, 33146	4.9	17
34	Cancer Stem Cells and the Microenvironment **2015**, 157-164.e3		1
33	The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors. *Molecular Cancer*, **2015**, 14, 6	42.1	16
32	Regulation of Breast Cancer Stem Cells by Mesenchymal Stem Cells in the Metastatic Niche **2015**, 123-143		
31	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. *Oncogene*, **2015**, 34, 671-80	9.2	58
30	Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. *Scientific Reports*, **2015**, 5, 15821	4.9	43
29	Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. *Molecular Cancer Therapeutics*, **2015**, 14, 779-787	6.1	88
28	Breast cancer stem cells: we've got them surrounded. *Clinical Cancer Research*, **2013**, 19, 511-3	12.9	25
27	Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. *Clinical Cancer Research*, **2013**, 19, 1972-80	12.9	148
26	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. *Cancer Research*, **2013**, 73, 1635-46	10.1	186
25	HER2 and breast cancer stem cells: more than meets the eye. *Cancer Research*, **2013**, 73, 3489-93	10.1	96
24	Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. *PLoS ONE*, **2013**, 8, e82821	3.7	51

23	Breast Cancer Stem Cells: Responsible for Therapeutic Resistance and Relapse? **2013**, 385-398		1
22	Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. *Breast Cancer Research and Treatment*, **2012**, 135, 913-22	4.4	34
21	Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. *Molecular Cell*, **2012**, 47, 570-84	17.6	385
20	Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies. *Current Breast Cancer Reports*, **2012**, 4, 225-231	0.8	2
19	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2784-9	11.5	551
18	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. *PLoS Genetics*, **2012**, 8, e1002751	6	136
17	Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. *Cancer Research*, **2011**, 71, 614-24	10.1	476
16	Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. *Clinical Cancer Research*, **2011**, 17, 6125-9	12.9	239
15	Breast cancer stem cells, cytokine networks, and the tumor microenvironment. *Journal of Clinical Investigation*, **2011**, 121, 3804-9	15.9	450
14	Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. *Clinical Cancer Research*, **2010**, 16, 2580-90	12.9	406
13	Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. *Breast Cancer Research and Treatment*, **2010**, 122, 777-85	4.4	372
12	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *Journal of Clinical Investigation*, **2010**, 120, 485-97	15.9	577
11	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biology*, **2009**, 7, e1000121	9.7	414
10	HER-2, notch, and breast cancer stem cells: targeting an axis of evil. *Clinical Cancer Research*, **2009**, 15, 1845-7	12.9	116
9	HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. *Oncogene*, **2008**, 27, 6120-30	9.2	454
8	Selective targeting of cancer stem cells: a new concept in cancer therapeutics. *BioDrugs*, **2007**, 21, 299-310	7.9	105
7	Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts. *Journal of Biological Chemistry*, **2005**, 280, 10253-63	5.4	21
6	The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase. *Journal of Biological Chemistry*, **2004**, 279, 28345-57	5.4	70

5	The interplay between Src family kinases and receptor tyrosine kinases. *Oncogene*, **2004**, 23, 7957-68	9.2	376
4	Hepatitis viruses and the MAPK pathway: is this a survival strategy?. *Virus Research*, **2003**, 92, 131-40	6.4	68
3	The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2. *Journal of Biological Chemistry*, **2002**, 277, 22759-67	5.4	98
2	The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. *Journal of Biological Chemistry*, **2001**, 276, 42389-400	5.4	115
1	The critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment		5